Rosacea Market

DelveInsight's "Rosacea — Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the rosacea, historical and forecasted epidemiology as well as the rosacea market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan

The rosacea market report provides current treatment practices, emerging drugs, rosacea market share of the individual therapies, current and forecasted rosacea market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current rosacea treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom)
• Japan

Study Period: 2019–2032

Rosacea Disease Understanding and Treatment Algorithm

The DelveInsight’s rosacea market report gives a thorough understanding of rosacea by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Rosacea is a characteristic condition that affects the skin by causing facial erythema or redness. Around one in 10 people in the world is affected by rosacea. The symptoms of the disease manifest in various combinations and severity that often fluctuates between periods of exacerbation and remission.

It is a common skin condition that causes redness and visible blood vessels in central part of the face. It may also produce small, red, pus-filled bumps. These signs and symptoms may flare up for a period of weeks to months and then diminish for a while. Rosacea sometimes can be mistaken for acne (an allergic reaction or other skin problems).

Diagnosis

No specific test is used to diagnosis rosacea. Instead, diagnosis is based on the history of symptoms and an examination of skin.

Treatment

The current therapeutic landscape of rosacea can be divided into four major categories based on the route of administration and the approved usage for the condition. These are: topical retinoids, topical antibiotics, oral tetracycline class antibiotics (TCAs), and oral retinoid.

Rosacea Epidemiology

The rosacea epidemiology section provides insights about historical and current rosacea patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

As per the article by Mandal (n.d.), titled “Rosacea Epidemiology,” in the United States, the prevalence of rosacea seems to be on the rise and in the United Kingdom, the prevalence is 1.65 per 1000 person-years. There is a paucity of epidemiological data on rosacea, with reported prevalence rates ranging from as little as 0.09% to as much as 22.00%.

The disease epidemiology covered in the report provides historical as well as forecasted rosacea epidemiology segmented as Total Prevalent Population of Rosacea, Gender‐specific Prevalent Population of Rosacea, Diagnosed and Treatable Prevalence of Rosacea, Subtype-specific Diagnosed Prevalence of Rosacea and Severity-specific Diagnosed Prevalence of Rosacea in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

Country Wise- Rosacea Epidemiology

This section provides glimpse of the rosacea epidemiology in the United States, EU4 (Germany, Spain, Italy, France) and United Kingdom, and the Japan

Rosacea Drug Chapters

The drug chapter segment of the rosacea report encloses the detailed analysis of rosacea marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the rosacea clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Rosacea Marketed Drugs

Epsolay: Sol-Gel

In April 2022, the FDA has approved Epsolay (VERED), an encapsulated benzoyl peroxide cream with a 5% concentration for the treatment of patients with inflammatory lesions of rosacea in adults.

Finacea: Bayer

In July 2015, the US FDA approved Bayer HealthCares Finacea Foam 15%, for treatment of mild to moderate rosacea.

Note: Detailed Current therapies assessment will be provided in the full report of rosacea

Rosacea Emerging Drugs

ACU-D1 (Accuitis) is and investigational therapy, which has activity against the 26S proteasome, one of the beneficial effects of blocking the proteasome is to inhibit the transcription factor nuclear factor kappa beta (NFkB), which is a potent mediator of inflammation. NFkB is a mediator of skin diseases including Rosacea, Psoriasis, and Acne.

B244 (AOBiome) is developing B244, which was evaluated in Phase II clinical trial for the treatment of rosacea. Ammonia Oxidizing Bacteria, or AOB, a human commensal with well-understood and well-characterized biochemical properties that are critical to human health.

Note: Detailed emerging therapies assessment will be provided in the full report of rosacea

Rosacea Market Outlook

The market comprises a variety of options for the treatment of rosacea, among topical therapies, topical retinoids mainly include Tretinoin, Tazarotene, Adapalene, and Clindamycin/tretinoin, and several others are used to reduce erythema, papules and pustules, and telangiectasias. Among these, Tretinoin has the lowest cost and most commonly prescribed topical retinoid, accounting for majority of the population.

Topical antibiotics, such as metronidazole (e.g. Metrolotion), clindamycin, erythromycin, azelaic acid (e.g. Fincea), benzoyl peroxide, benzoyl peroxide/clindamycin, benzoyl peroxide/erythromycin, sulfacetamide, and sulfacetamide/sulfur, are applied directly to the skin to kill bacteria on the surface of skin.

Initial therapy for moderate to severe rosacea should include oral treatment or a combination of topical and oral treatments. Because rosacea is a chronic disease, the long-term use of antibiotics can lead to adverse effects. Additionally, concerns about long-term use of antibiotics leading to resistant bacterial strains need to be addressed.

Key players such as Accuitis, AOBiome along with few others are involved in developing therapies for rosacea.

According to DelveInsight, rosacea market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of rosacea is very robust, many potential therapies are being investigated for the treatment of rosacea, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the rosacea market in the 7MM. Aside from that, the market size of rosacea may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of rosacea may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Rosacea Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the rosacea market or expected to get launched in the market during the study period 2019-2032. The analysis covers rosacea market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of rosacea.

Rosacea Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses rosacea key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for rosacea emerging therapies.

Reimbursement Scenario in Rosacea

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the rosacea domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or rosacea market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the rosacea Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of rosacea, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the rosacea epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for rosacea are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the rosacea market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global rosacea market

Report Highlights

• In the coming years, the rosacea market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence rosacea R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for rosacea. The launch of emerging therapies will significantly impact the rosacea market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for rosacea
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Rosacea Report Insights

• Patient Population
• Therapeutic Approaches
• Rosacea Pipeline Analysis
• Rosacea Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Rosacea Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Rosacea Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Rosacea Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the rosacea drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the rosacea total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest rosacea market size during the forecast period (2019-2032)?
• At what CAGR, the rosacea market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the rosacea market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the rosacea market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of rosacea?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• What is the historical rosacea patient pool in seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• What would be the forecasted patient pool of rosacea in seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about rosacea?
• Out of all 7MM countries, which country would have the highest prevalence population of rosacea during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the rosacea treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of rosacea in the USA, Europe, and Japan?
• What are the rosacea marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of rosacea?
• How many therapies are in-development by each company for rosacea treatment?
• How many are emerging therapies in mid-stage, and late stage of development for rosacea treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the rosacea therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for rosacea and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for rosacea?
• What are the global historical and forecasted markets of rosacea?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the rosacea market
• Organize sales and marketing efforts by identifying the best opportunities for rosacea in the US, Europe (Germany, Spain, Italy, France and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the rosacea market
• To understand the future market competition in the rosacea market